Cytokinstormer ved covid-19?

Tveito, Kari

doi:10.4045/tidsskr.20.0239

Cited by 25 publications

(20 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study showed that patients with low HDL-C level had higher proportion of severe events, while further regression analysis also revealed that low HDL-C was an independent risk factor for severe events in COVID-19. Hence, HDL-C may serve in a protective role in COVID-19, Excessive inflammation is one of the important features of COVID-19 patients, especially in patients with severe cases or in those who have died [31][32][33][34]. It is often manifested by a marked increase in inflammatory factors, such as CRP and interleukins [3,35].…”

Section: Discussionmentioning

confidence: 99%

Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study

et al. 2020

View full text Add to dashboard Cite

Background: The purpose of the study is to describe the blood lipid levels of patients diagnosed with coronavirus disease 2019 (COVID-19) and to analyze the correlation between blood lipid levels and the prognosis of COVID-19 patients. Methods: In the clinical retrospective analysis, a total of 228 adults infected with COVID-19 were enrolled between January 17, 2020 and March 14, 2020, in Changsha, China. One thousand one hundred and forty healthy participants with matched age and gender were used as control. Median with interquartile range and Mann-Whitney test were adopted to describe and analyze clinical data. The Kaplan-Meier (KM) curve and Cox regression analysis were used to analyze the correlation between high-density lipoprotein cholesterol (HDL-C) and the severity of COVID-19. Results: Compared with control, COVID-19 patients showed significantly lower levels of total cholesterol (TC) [median, 3.76 vs 4.65 mmol/L, P = 0.031], triglyceride [median, 1.08 vs 1.21 mmol/L, P < 0.001], low-density lipoprotein cholesterol (LDL-C) [median, 2.63 vs 2.83 mmol/L, P < 0.001], and HDL-C [median, 0.78 vs 1.37 mmol/L, P < 0.001], while compared with non-severe patients, severe COVID-19 patients only presented lower levels of HDL-C [median, 0.69 vs 0.79 mmol/L, P = 0.032]. In comparison with patients with high HDL-C, patients with low HDL-C showed a higher proportion of male (69.57% vs 45.60%, P = 0.004), higher levels of C-reactive protein (CRP) (median, 27.83 vs 12.56 mg/L, P < 0.001) and higher proportion of severe events (36.96% vs 14.84%, P = 0.001). Moreover, patients with low HDL-C at admission showed a higher risk of developing severe events compared with those with high HDL-C (Log Rank P = 0.009). After adjusting for age, gender and underlying diseases, they still had elevated possibility of developing severe cases than those with high HDL-C (HR 2.827, 95% CI 1.190-6.714, P = 0.019). Conclusions: HDL-C level was lower in COVID-19 adult patients, and low HDL-C in COVID-19 patients was correlated with a higher risk of developing severe events.

show abstract

Section: Discussionmentioning

confidence: 99%

Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Further release of IL 6 causes vascular leakage, activation of complement and coagulation cascade, disseminated intravascular coagulation and end organ damage. 17 , 18…”

Section: Immune Mediated Injurymentioning

confidence: 99%

Neurological Manifestations and Complications of COVID-19: A Literature Review

Ahmad

Rathore

2020

Preprint

151

196

View full text Add to dashboard Cite

The Coronavirus disease due to SARS-CoV-2 emerged in Wuhan city, China in December 2109 and rapidly spread more than 200 countries as a global health pandemic. There are more million confirmed cases and around 165,000 fatalities. The primary manifestation is respiratory and cardiac but neurological manifestations are being reported in the literature as case reports and case series. The most common reported symptoms to include headache and dizziness followed by encephalopathy and delirium. Among the complications noted are Cerebrovascular accident, Guillian barre syndrome, acute transverse myelitis, and acute encephalitis. The most common peripheral manifestation was hyposmia. It is further noted that sometimes the neurological manifestations can precede the typical features like fever and cough and later on typical manifestations develop in these patients. Hence a high index of suspicion is required for timely diagnosis and isolation of cases to prevent the spread in neurology wards. We provide a narrative review of the important manifestations and complications of Coronavirus reported in the global literature so far.

show abstract

“…One of the most widely accepted neuropathological mechanisms of SARS-CoV-2 is hyper-inflammatory state ( Yavarpour-Bali and Ghasemi-Kasman, 2020 ). Accordingly, the immune-mediated damage is resulted from cytokine storms, as well as the activation of T lymphocytes, endothelial cells, and macrophages which leads into vascular leakage, coagulation, and end-organ damage ( Mehta et al, 2020 ; Tveito, 2020 ). It was shown that coronavirus triggers innate immunity associated with the release of microglial-induced INF-α/β ( Savarin et al, 2018 ).…”

Section: The Pathophysiological Mechanistic Pathways Of Coronavirusesmentioning

confidence: 99%

Targeting Neurological Manifestations of Coronaviruses by Candidate Phytochemicals: A Mechanistic Approach

et al. 2021

View full text Add to dashboard Cite

The novel coronavirus 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a wide range of manifestations. In this regard, growing evidence is focusing on COVID-19 neurological associations; however, there is a lack of established pathophysiological mechanisms and related treatments. Accordingly, a comprehensive review was conducted, using electronic databases, including PubMed, Scopus, Web of Science, and Cochrane, along with the author’s expertize in COVID-19 associated neuronal signaling pathways. Besides, potential phytochemicals have been provided against neurological signs of COVID-19. Considering a high homology among SARS-CoV, Middle East Respiratory Syndrome and SARS-CoV-2, revealing their precise pathophysiological mechanisms seems to pave the road for the treatment of COVID-19 neural manifestations. There is a complex pathophysiological mechanism behind central manifestations of COVID-19, including pain, hypo/anosmia, delirium, impaired consciousness, pyramidal signs, and ischemic stroke. Among those dysregulated neuronal mechanisms, neuroinflammation, angiotensin-converting enzyme 2 (ACE2)/spike proteins, RNA-dependent RNA polymerase and protease are of special attention. So, employing multi-target therapeutic agents with considerable safety and efficacy seems to show a bright future in fighting COVID-19 neurological manifestations. Nowadays, natural secondary metabolites are highlighted as potential multi-target phytochemicals in combating several complications of COVID-19. In this review, central pathophysiological mechanisms and therapeutic targets of SARS-CoV-2 has been provided. Besides, in terms of pharmacological mechanisms, phytochemicals have been introduced as potential multi-target agents in combating COVID-19 central nervous system complications.

show abstract

Cytokinstormer ved covid-19?

Cited by 25 publications

References 5 publications

Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study

Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study

Neurological Manifestations and Complications of COVID-19: A Literature Review

Targeting Neurological Manifestations of Coronaviruses by Candidate Phytochemicals: A Mechanistic Approach

Contact Info

Product

Resources

About